S&P: Wyeth unaffected

Standard & Poor's said Wyeth's recent announcement that the FDA is requesting an additional lengthy clinical trial for its drug prospect Pristiq does not have an impact on the company's current ratings or outlook.

S&P said that while the lengthy delay of Pristiq is a blow to Wyeth's long-term prospects, it still has one of the deeper late-stage product pipelines in the industry, with six planned new product launches, excluding Pristiq, over the next 18 months.

The agency said it believes that the company's current portfolio, which includes fast-growing blockbusters Enbrel and Prevnar, full product pipeline and strong financial profile all adequately support the current ratings and outlook.

But the pressure on Wyeth to produce significant new products has increased in light of Pristiq's lengthy approval delay and possible damage to its sales potential, the agency said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.